Date: Jul 01, 2011 Source: (
click here to go to the source)
As of July 1, 2011 GENOVAC has officially changed it's name to Aldevron Freiburg. The core team and technologies will remain intact.
As of July 1, 2011 GENOVAC has officially changed it's name to Aldevron Freiburg. The core team and technologies will remain intact. Representing the antibody arm of Aldevron, Aldevron Freiburg will continue being a world leader in genetic immunization utilizing GENOVAC Antibody Technology™.
GENOVAC product and services have been migrated to the Aldevron website and are available at aldevron.com/genovac. If you have any questions, please do not hesitate to contact Aldevron.
GENOVAC was first registered as a limited company (GmbH) in December 1999 in Freiburg im Breisgau, South West Germany, by Fritz Grunert, John Thompson and Wolfgang Zimmermann. The three founders were group leaders at the Institute of Immunobiology, University of Freiburg and have a longstanding experience in tumor biology and the development of antibodies against carcinoembryonic antigen (CEA) and related molecules. During this time, they built up contacts to top laboratories working in the field of tumor biology worldwide.
On January 1, 2004 GENOVAC became a part of Aldevron LLC, USA. Both companies have specialized in the area of genetic immunization to develop antibodies. The combined expertise and clientele continue to strengthen Aldevron as a world-leader in antibody technology.
Aldevron Freiburg is based in Freiburg, Germany, which is located in the middle of one of the largest biotechnology centers (BioValley) at a three nation border in the heart of Europe. This region includes Basel, Freiburg and Strasbourg, which apart from a concentration of large pharmaceutical companies (e.g., Novartis and Roche) all have well-known universities and research institutes (e.g., Friedrich Miescher Institute, Basel and Max-Planck Institute of Immunology in Freiburg)
